Schedule of Financial Information by Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Segment Reporting Information [Line Items]
Net revenues	$ 11,426	$ 14,681
Cost of revenues (excluding amortization of acquired intangible assets)	3,554	1,640
Direct expenses	17,990	19,871
Segment contribution	(10,118)	(6,830)
Indirect expenses	368	546
Loss from operations	(10,486)	(7,376)
Amortization	368	546
Cell Therapy [Member]
Segment Reporting Information [Line Items]
Net revenues	264
Cost of revenues (excluding amortization of acquired intangible assets)
Direct expenses	3,257	5,465
Segment contribution	(2,993)	(5,465)
BioBanking [Member]
Segment Reporting Information [Line Items]
Net revenues	1,408	1,287
Cost of revenues (excluding amortization of acquired intangible assets)	209	177
Direct expenses	369	416
Segment contribution	830	694
Degenerative Disease [Member]
Segment Reporting Information [Line Items]
Net revenues	9,754	13,394
Cost of revenues (excluding amortization of acquired intangible assets)	3,345	1,463
Direct expenses	4,747	4,414
Segment contribution	1,662	7,517
Other [Member]
Segment Reporting Information [Line Items]
Net revenues
Cost of revenues (excluding amortization of acquired intangible assets)
Direct expenses	9,617	9,576
Segment contribution	(9,617)	(9,576)
Indirect expenses		546
Amortization	368	546
Total other	$ 368	$ 546